Pneumococcal Disease
Wyeth Receives Positive Opinion from European Regulators for its 13-valent Pneumococcal Candidate Vaccine for Infants and Young Children
Published in Vaccine Weekly, October 14th, 2009
Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced that the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the company's pneumococcal conjugate vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent Adsorbed]). The CHMP recommends approval of Prevenar 13 for active immunization of children aged 6 weeks to 5 years for the prevention of invasive pneumococcal disease, as well as pneumonia and otitis media (middle ear infection) caused by 13 pneumococcal serotypes. The CHMP's opinion for Prevenar 13 will now be forwarded to the European Commission and a final decision is expected...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2009-10-14)
More Articles from Vaccine Weekly
- McGill University Health Centre
Study highlights HIV/AIDS challenge in American prison system - NIH/National Institute of Allergy and Infectious Diseases
Frozen assets: NIAID researchers turn to unique resource for clues to norovirus evolution - University of Southern California
Prenatal exposure to flu pandemic increased chances of heart disease - German Measles
Research from J.K. Louie and co-researchers in the area of german measles published - Hepatitis B Virus
Groundbreaking Primate Study Links Mercury Vaccine Preservative to Brain Injury - Immunization
Study findings from D. Mcilroy et al provide new insights into immunization - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
